NZ603527A - Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules - Google Patents

Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules

Info

Publication number
NZ603527A
NZ603527A NZ603527A NZ60352711A NZ603527A NZ 603527 A NZ603527 A NZ 603527A NZ 603527 A NZ603527 A NZ 603527A NZ 60352711 A NZ60352711 A NZ 60352711A NZ 603527 A NZ603527 A NZ 603527A
Authority
NZ
New Zealand
Prior art keywords
cholesterol
vaccines
cpg
carrier molecules
sole adjuvant
Prior art date
Application number
NZ603527A
Other languages
English (en)
Inventor
Risini Dhammika Weeratna
Heather Lynn Davis
Paul Joseph Dominowski
Original Assignee
Zoetis Belgium S A
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=44626939&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NZ603527(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Zoetis Belgium S A filed Critical Zoetis Belgium S A
Publication of NZ603527A publication Critical patent/NZ603527A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/13—Amines
    • A61K31/155—Amidines (), e.g. guanidine (H2N—C(=NH)—NH2), isourea (N=C(OH)—NH2), isothiourea (—N=C(SH)—NH2)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/099—Bordetella
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/155—Paramyxoviridae, e.g. parainfluenza virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/12—Viral antigens
    • A61K39/245—Herpetoviridae, e.g. herpes simplex virus
    • A61K39/265—Infectious rhinotracheitis virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5252—Virus inactivated (killed)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525—Virus
    • A61K2039/5254—Virus avirulent or attenuated
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55505—Inorganic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55561—CpG containing adjuvants; Oligonucleotide containing adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55577—Saponins; Quil A; QS21; ISCOMS
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6037—Bacterial toxins, e.g. diphteria toxoid [DT], tetanus toxoid [TT]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/70—Multivalent vaccine
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/16011—Herpesviridae
    • C12N2710/16711—Varicellovirus, e.g. human herpesvirus 3, Varicella Zoster, pseudorabies
    • C12N2710/16734—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18511—Pneumovirus, e.g. human respiratory syncytial virus
    • C12N2760/18534—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2760/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses negative-sense
    • C12N2760/00011—Details
    • C12N2760/18011—Paramyxoviridae
    • C12N2760/18611—Respirovirus, e.g. Bovine, human parainfluenza 1,3
    • C12N2760/18634—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24311—Pestivirus, e.g. bovine viral diarrhea virus
    • C12N2770/24334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/32011—Picornaviridae
    • C12N2770/32311—Enterovirus
    • C12N2770/32334—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Virology (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
NZ603527A 2010-05-28 2011-05-27 Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules NZ603527A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US34924410P 2010-05-28 2010-05-28
PCT/IB2011/052347 WO2011148356A1 (en) 2010-05-28 2011-05-27 Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules

Publications (1)

Publication Number Publication Date
NZ603527A true NZ603527A (en) 2014-10-31

Family

ID=44626939

Family Applications (1)

Application Number Title Priority Date Filing Date
NZ603527A NZ603527A (en) 2010-05-28 2011-05-27 Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules

Country Status (22)

Country Link
US (1) US10456463B2 (da)
EP (1) EP2575878B1 (da)
JP (3) JP2011251963A (da)
KR (1) KR101528021B1 (da)
CN (1) CN103025351B (da)
AU (2) AU2011259718B2 (da)
BR (1) BR112012030337B1 (da)
CA (1) CA2800158C (da)
CL (1) CL2012003299A1 (da)
DK (1) DK2575878T3 (da)
ES (1) ES2683316T3 (da)
HR (1) HRP20181039T1 (da)
HU (1) HUE038894T2 (da)
LT (1) LT2575878T (da)
MX (1) MX347471B (da)
NZ (1) NZ603527A (da)
PL (1) PL2575878T3 (da)
PT (1) PT2575878T (da)
RS (1) RS57428B1 (da)
SI (1) SI2575878T1 (da)
WO (1) WO2011148356A1 (da)
ZA (1) ZA201208837B (da)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8552165B2 (en) * 2008-12-09 2013-10-08 Heather Davis Immunostimulatory oligonucleotides
SI2759306T1 (sl) * 2008-12-09 2016-05-31 Coley Pharmaceutical Group, Inc. Imunostimulacijski oligonukleotidi
US9314519B2 (en) * 2012-08-21 2016-04-19 Intervet Inc. Liquid stable virus vaccines
EP3542819B1 (en) * 2013-05-14 2021-08-18 Zoetis Services LLC Novel vaccine compositions comprising immunostimulatory oligonucleotides
ES2750608T3 (es) 2013-07-25 2020-03-26 Exicure Inc Construcciones esféricas a base de ácido nucleico como agentes inmunoestimulantes para uso profiláctico y terapéutico
JP6586083B2 (ja) * 2013-09-19 2019-10-02 ゾエティス・サービシーズ・エルエルシー 油性アジュバント
AU2014337452A1 (en) 2013-10-17 2016-04-21 Zoetis Services Llc Methods and compositions for treatment of S. equi infection
BR112016012127A2 (pt) * 2013-11-26 2017-09-26 Zoetis Services Llc composições para a indução da resposta imunológica
KR102290205B1 (ko) 2014-06-04 2021-08-20 엑시큐어, 인크. 예방 또는 치료 용도를 위한 리포솜성 구형 핵산에 의한 면역 조절인자의 다가 전달
KR20170097116A (ko) * 2015-01-16 2017-08-25 조에티스 서비시즈 엘엘씨 구제역 백신
US10456459B2 (en) * 2015-07-20 2019-10-29 Zoetis Services Llc Liposomal adjuvant compositions
ES2878475T3 (es) * 2015-07-20 2021-11-18 Zoetis Services Llc Composiciones adyuvantes liposomales
JP7076798B2 (ja) 2015-09-09 2022-05-30 清華大学 効果的なワクチンアジュバントとするメバロン酸経路の阻害剤
CN107149671B (zh) * 2016-03-03 2021-02-05 郭文江 一种药物组合物及其应用
WO2018039629A2 (en) 2016-08-25 2018-03-01 Northwestern University Micellar spherical nucleic acids from thermoresponsive, traceless templates
WO2018209270A1 (en) 2017-05-11 2018-11-15 Northwestern University Adoptive cell therapy using spherical nucleic acids (snas)
SG11202004773SA (en) 2017-12-15 2020-06-29 Bayer Animal Health Gmbh Immunostimulatory compositions
BR112022000347A2 (pt) * 2019-07-12 2022-04-12 Res Found Dev Vacinas de ehrlichia e composições imunogênicas
IT202100014747A1 (it) * 2021-06-07 2022-12-07 Consiglio Nazionale Ricerche Derivati sterolici come nuovi ligandi del recettore dectina-1 nel trattamento terapeutico di patologie correlate a tale recettore
CN115645417A (zh) * 2022-10-17 2023-01-31 武汉轻工大学 鹅去氧胆酸在制备治疗或预防猪病毒性腹泻的药物或饲料添加剂中的应用
CN118059219B (zh) * 2024-04-19 2024-06-25 西南交通大学 一种肥胖相关乳腺癌的个性化核酸疫苗及其制备方法

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4469863A (en) 1980-11-12 1984-09-04 Ts O Paul O P Nonionic nucleic acid alkyl and aryl phosphonates and processes for manufacture and use thereof
US5023243A (en) 1981-10-23 1991-06-11 Molecular Biosystems, Inc. Oligonucleotide therapeutic agent and method of making same
JP2547714B2 (ja) 1981-10-23 1996-10-23 モルキユラ− バイオシステムズ インコ−ポレテツド オリゴヌクレオチド治療剤及びその製法
DE4321946A1 (de) 1993-07-01 1995-01-12 Hoechst Ag Methylphosphonsäureester, Verfahren zu deren Herstellung und deren Verwendung
US6207646B1 (en) 1994-07-15 2001-03-27 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
US6239116B1 (en) 1994-07-15 2001-05-29 University Of Iowa Research Foundation Immunostimulatory nucleic acid molecules
ATE328890T1 (de) * 1994-07-15 2006-06-15 Univ Iowa Res Found Immunomodulatorische oligonukleotide
GB9718901D0 (en) * 1997-09-05 1997-11-12 Smithkline Beecham Biolog Vaccine
DK1104306T3 (da) 1998-08-10 2006-05-22 Antigenics Inc Præparater af CpG- og saponinadjuvanser og fremgangsmåder til anvendelse deraf
FR2783170B1 (fr) * 1998-09-11 2004-07-16 Pasteur Merieux Serums Vacc Emulsion immunostimulante
GB9921146D0 (en) * 1999-09-07 1999-11-10 Smithkline Beecham Biolog Novel composition
US6949520B1 (en) 1999-09-27 2005-09-27 Coley Pharmaceutical Group, Inc. Methods related to immunostimulatory nucleic acid-induced interferon
JP2003510290A (ja) 1999-09-27 2003-03-18 コーリー ファーマシューティカル グループ，インコーポレイテッド 免疫刺激核酸誘導インターフェロンに関する方法
CN1301572A (zh) * 1999-10-28 2001-07-04 上海生物制品研究所 用于疫苗的佐剂组合物
US7129222B2 (en) * 2000-03-10 2006-10-31 Dynavax Technologies Corporation Immunomodulatory formulations and methods for use thereof
EP1446162B1 (en) 2001-08-17 2008-10-15 Coley Pharmaceutical GmbH Combination motif immune stimulatory oligonucleotides with improved activity
GB0123580D0 (en) 2001-10-01 2001-11-21 Glaxosmithkline Biolog Sa Vaccine
MXPA04003900A (es) * 2001-11-07 2004-07-08 Cytos Biotechnology Ag Disposiciones de antigenos para el tratamiento de enfermedades oseas.
JP2005526497A (ja) * 2002-02-04 2005-09-08 ビオミラ，インコーポレーテッド 免疫刺激性、共有結合性脂質化オリゴヌクレオチド
KR20050052467A (ko) * 2002-08-12 2005-06-02 다이나박스 테크놀로지 코퍼레이션 면역조절 조성물, 이의 제조방법 및 이의 이용방법
JP2007516219A (ja) * 2003-05-07 2007-06-21 アヴェンティス パストゥール インコーポレイテッド 髄膜炎菌ワクチン接種に対する免疫原性の増強の方法
WO2005021726A2 (en) * 2003-08-28 2005-03-10 The Immune Response Corporation Immunogenic hiv compositions and related methods
GB0323965D0 (en) * 2003-10-13 2003-11-19 Glaxosmithkline Biolog Sa Immunogenic compositions
US20050175630A1 (en) * 2003-12-23 2005-08-11 Eyal Raz Immunogenic compositions and methods of use thereof
WO2005107797A1 (en) * 2004-03-09 2005-11-17 Chiron Corporation Influenza virus vaccines
CA2557443A1 (en) * 2004-03-12 2005-09-29 Hybridon, Inc. Enhanced activity of hiv vaccine using a second generation immunomodulatory oligonucleotide
AU2005333126A1 (en) * 2004-07-18 2006-12-21 Csl Limited Methods and compositions for inducing innate immune responses
ATE521621T1 (de) * 2004-11-29 2011-09-15 Changchun Huapu Biotechnology Co Ltd Cpg-einzelstrang-desoxynukleotide zur verwendung als adjuvans
EP1849780A1 (en) * 2006-04-21 2007-10-31 De Staat der Nederlanden, vert. door de minister van VWS Vaccine against nicotine addiction
AU2007268534B2 (en) * 2006-05-31 2011-07-14 Osaka University Immunostimulatory oligonucleotide and pharmaceutical application thereof
PT2078080E (pt) 2006-09-27 2015-09-18 Coley Pharm Gmbh Análogos dos oligonucleotídeos cpg que contêm análogos t hidrofóbicos com atividade imunoestimulante potenciada
MX2009012482A (es) * 2007-05-17 2009-12-02 Coley Pharm Group Inc Oligonucleotidos de clase a con potencia inmunoestimuladora.
CA2710983A1 (en) * 2007-12-27 2009-10-01 The Ohio State University Research Foundation Lipid nanoparticle compositions and methods of making and using the same
WO2009156960A2 (en) * 2008-06-27 2009-12-30 Pfizer Inc. Novel adjuvant compositions

Also Published As

Publication number Publication date
KR20130069668A (ko) 2013-06-26
MX347471B (es) 2017-04-24
PT2575878T (pt) 2018-10-03
PL2575878T3 (pl) 2018-12-31
LT2575878T (lt) 2018-11-12
JP2013532140A (ja) 2013-08-15
EP2575878B1 (en) 2018-06-13
AU2016203611A1 (en) 2016-06-16
JP2011251963A (ja) 2011-12-15
BR112012030337A2 (pt) 2017-01-24
AU2011259718A1 (en) 2012-12-06
HRP20181039T1 (hr) 2018-08-24
JP6133482B2 (ja) 2017-05-24
KR101528021B1 (ko) 2015-06-10
JP2017048187A (ja) 2017-03-09
US10456463B2 (en) 2019-10-29
SI2575878T1 (sl) 2018-12-31
CA2800158A1 (en) 2011-12-01
CN103025351B (zh) 2016-08-24
CA2800158C (en) 2020-07-21
US20130084306A1 (en) 2013-04-04
HUE038894T2 (hu) 2018-12-28
JP6034285B2 (ja) 2016-11-30
EP2575878A1 (en) 2013-04-10
CL2012003299A1 (es) 2013-03-08
ZA201208837B (en) 2013-08-28
DK2575878T3 (da) 2018-08-13
CN103025351A (zh) 2013-04-03
AU2011259718B2 (en) 2016-03-03
WO2011148356A1 (en) 2011-12-01
BR112012030337B1 (pt) 2021-04-27
AU2016203611B2 (en) 2017-06-15
ES2683316T3 (es) 2018-09-26
RS57428B1 (sr) 2018-09-28
MX2012013731A (es) 2013-12-16

Similar Documents

Publication Publication Date Title
NZ603527A (en) Vaccines comprising cholesterol and cpg as sole adjuvant - carrier molecules
NZ737757A (en) Peptide oligonucleotide conjugates
MX2013004338A (es) Secuencias de repeticiones palindromicas cortas separadas regularmente agrupadas-cas (crisp-cas).
MX2021006342A (es) Mutantes de virus de influenza y usos para los mismos.
WO2015066634A3 (en) Optimal soybean loci
WO2013026740A3 (en) Methods and means to modify a plant genome
EP3698631A3 (en) Methods of delivering oligonucleotides to immune cells
UA103316C2 (uk) Вакцини на базі флавівірусів з дефектною реплікацією і вектори для одержання вакцин
MX343048B (es) Oligodesoxinucleotidos inmunoestimulantes.
EP2569330A4 (en) CHLOROTOXINE VARIANTS, CONJUGATES, AND METHODS OF USE THEREOF
MX2013013800A (es) Oligodesoxinucleotidos inmunoestimuladores.
IL214385A0 (en) Inactivated dengue virus vaccine with aluminium-free adjuvant
IN2014DN00078A (da)
NZ606087A (en) Influenza vaccine
MX348785B (es) Metodos y medios para modificar un genoma vegetal en un sitio preseleccionado.
MX2013003245A (es) Vacuna contra virus de diarrea viral de bovinos.
WO2013052095A3 (en) Vaccine
AP2010005446A0 (en) Inactivated live-attenuated bluetongue virus vaccine.
WO2014008475A3 (en) Compositions and methods related to viral vaccines
MX350718B (es) Vacuna de rinitis equina.
MX2011005281A (es) Vacuna marcadora de salmonella.
WO2013049535A3 (en) Influenza vaccine
WO2012003030A3 (en) Methods of identifying & using anti-viral compounds
AP2010005333A0 (en) Vaccine comprising a ribosomal protein extract (RPE) and optionally a thi-promoting adjuvant.
GB0818080D0 (en) Immunogenic peptides

Legal Events

Date Code Title Description
ASS Change of ownership

Owner name: ZOETIS BELGIUM S.A., BE

Effective date: 20130426

PSEA Patent sealed
RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2016 BY BALDWINS INTELLECTUAL PROPERTY

Effective date: 20150302

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2017 BY THOMSON REUTERS

Effective date: 20160415

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2018 BY THOMSON REUTERS

Effective date: 20170421

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2019 BY THOMSON REUTERS

Effective date: 20180418

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2020 BY THOMSON REUTERS

Effective date: 20190417

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2021 BY THOMSON REUTERS

Effective date: 20200417

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2022 BY THOMSON REUTERS

Effective date: 20210403

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2023 BY THOMSON REUTERS

Effective date: 20220402

RENW Renewal (renewal fees accepted)

Free format text: PATENT RENEWED FOR 1 YEAR UNTIL 27 MAY 2024 BY THOMSON REUTERS

Effective date: 20230403